News & Updates

The adoption rate of germline genetic testing among individuals diagnosed with cancer in some states in the US over a period of 6 years remains subpar, with only 6.8 percent undergoing testing, as reported in a study.

Patients with genitourinary rhabdomyosarcoma who undergo organ-sparing treatment have higher odds of additional reconstructive surgery due to compromised urological function, reports a study.

In Chinese patients with stage N2–3 nasopharyngeal carcinoma (NPC) who have completed concurrent chemoradiotherapy (cCRT), adjuvant cisplatin-gemcitabine significantly improves progression-free survival (PFS) vs current standard of care (SoC) with adjuvant cisplatin-fluorouracil, according to a phase III trial at four cancer centres in China that was reported at ASCO 2023.

The combination of camrelizumab plus apatinib and temozolomide appears to be beneficial in the first-line treatment of advanced acral melanoma, with the majority of the patients showing response and an acceptable safety profile, according to the results of a phase II study.